Abstract
Alzheimer's Disease (AD) is one of the main causes of dementia worldwide, harming the lives of millions of people. Until recently, AD diagnostic methods relied mainly on clinical assessment, neuropsychological tests and neuroimaging, which were often only able to detect the disease in advanced stages, when changes in the brain were already significant and irreversible. In this context, blood biomarkers emerge, molecules present in the blood that reflect physiological and pathological processes, being widely used in the diagnosis, evaluation and staging of various diseases. Therefore, this work aims to evaluate the potential of blood biomarkers in the early diagnosis of AD. This is an integrative literature review with a search in the scientific databases of the Virtual Health Library (VHL) and PubMed, using the following descriptors: "Alzheimer's Disease", "Biomarkers" and "Early Diagnosis", together with Boolean operator “AND”. To better delimit the search, filters were added to the search to display only complete clinical studies, published in the last 5 years, in Portuguese, English and Spanish, for maximum reliability. At the end of the search, 13 were chosen articles to compose the sample of this study. The results showed that several biomarkers, with emphasis on amyloid proteins, TAU and NFL are associated with cognitive impairment, neurodegeneration and progression of AD, especially when evaluated together with already known risk factors, demonstrating good potential for use in the early diagnosis of AD, also with good precision.Further studies are needed to develop early diagnosis protocols, in addition to evaluating the feasibility of creating broad AD screening programs based on serum biomarkers.
References
ALVAREZ, X. A. et al. Modulation of Amyloid-β and Tau in Alzheimer’s Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. Journal of Alzheimer’s Disease, v. 90, n. 2, p. 705–717, 8 nov. 2022.
ASHTON, N. J. et al. Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest. JAMA Neurology, v. 80, n. 4, p. 388, 1 abr. 2023.
BODAGHI, Ali; FATTAHI, Nadia; RAMAZANI, Ali. Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon, v. 9, n. 2, p. e13323, 2023.
BREIJYEH, Zeinab; KARAMAN, Rafik. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules, v. 25, n. 24, p. 5789, 2020.
CULLEN, N. C. et al. Comparing progression biomarkers in clinical trials of early Alzheimer’s disease. Annals of Clinical and Translational Neurology, v. 7, n. 9, p. 1661–1673, 11 ago. 2020.
GAO, F. et al. Blood-based biomarkers for Alzheimer’s disease: a multicenter-based cross-sectional and longitudinal study in China. Science Bulletin, v. 68, n. 16, p. 1800–1808, ago. 2023.
HUANG, X. et al. Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer’s disease. CNS Neuroscience & Therapeutics, v. 30, n. 2, fev. 2024.
JUGANAVAR, Anup; JOSHI, Abhishek; SHEGEKAR, Tejas. Navigating Early Alzheimer’s Diagnosis: A Comprehensive Review of Diagnostic Innovations. Cureus, 2023.
KENNY, A. et al. Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. Biomolecules, v. 9, n. 11, p. 734, 13 nov. 2019.
LAYNO, Emily Bomasang; BRONSTHER, Rachel. Diagnosis and Treatment of Alzheimer’s Disease. Delaware Journal of Public Health, v. 7, n. 4, p. 74–85, 2021.
LI, Y. et al. Amyloid‐β protein and MicroRNA‐384 in NCAM‐Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer’s disease. CNS Neuroscience & Therapeutics, v. 28, n. 7, p. 1093–1107, 26 abr. 2022.
LORD, J. et al. Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer’s disease. Proceedings of the National Academy of Sciences, v. 118, n. 16, 16 abr. 2021.
MOSCOSO, A. et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, v. 78, n. 4, p. 396, 1 abr. 2021.
PONTECORVO, M. J. et al. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease. JAMA Neurology, v. 79, n. 12, p. 1250, 1 dez. 2022.
RAFFIN, J. et al. Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. The Journals of Gerontology: Series A, v. 76, n. 8, p. 1382–1390, 17 abr. 2021.
UDEH-MOMOH, C. et al. Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention. The Journal Of Prevention of Alzheimer’s Disease, p. 1–10, 2021.
WEST, T. et al. A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Molecular Neurodegeneration, v. 16, n. 1, 1 maio 2021.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Francisco Samuel Estrela Dantas, Maria Clara Maniçoba Ferreira de Lima, Paulo André Oliveira de Sá, Ludimilla da Costa Santos, Laryssa Ellen Vasconcelos Dias, Francisco Sóstenys Layo Nobre Silva, Willian Chaves Fraga, Danilo Ibero Mendes Fonseca, Antonio Charlles Ferreira da Silva, Felipe Augusto Cordeiro de Souza, Yalisson Frankli do Nascimento Fernandes, Gabriel Henrique Albuquerque Lins